Tag: Zilucoplan

The landscape of myasthenia gravis (MG) treatment has evolved beyond traditional immunosuppressants to include advanced, targeted injectable therapies. These newer options, including both subcutaneous injections and intravenous infusions, target specific components of the immune system to manage symptoms more effectively and improve quality of life.

In October 2023, the U.S. Food and Drug Administration (FDA) approved zilucoplan (brand name ZILBRYSQ®), which became the first self-administered, once-daily injection for myasthenia gravis (MG). This new treatment option offers a convenient and flexible alternative for eligible adults with generalized MG who are anti-acetylcholine receptor (AChR) antibody-positive.